Therapeutical Class：Carbapenems, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): not for MRSA; G(-); anaerobes.

Administraton：IV.

250-1000 mg every 6-8h, max 4 g/day.

Mild-infection: 250 mg q6h.

Moderate-infection: 500 mg q6-8h.

Severe infection: Full-susceptible organisms: 500 mg q6h.

Moderately-susceptible organisms: 1 g q6-8h.

Pseudomanas, neutropenic fever: 500 mg q6h.

UTI: Complicated: 500 mg q6h. Uncomplicated: 250 mg q6h. Infuse dose<500 mg over 20-30 min, >500 mg over 40-60 min; the infusion rate should be slowed down if nausea develops.

Renal impairment: Ccr 41-70 ml/min, 75% of dose;

Ccr 21-40 ml/min, 50% of dose;

Ccr <20 ml/min, 25% of dose.

Give a supplemental dose after hemodialysis.

Adverse Effect：Nausea, vomiting, rash (1-10%), diarrhea (1-10%), seizure (1-10%), erythema, thrombophlebitis.

Pregnancy Risk：C

Supply：Tienam XE “Tienam” Inj 500mg（500mg/500mg）（泰寧注射劑 MSD）＜10677＞